Cartesian Therapeutics, Inc. 10-K Item 1C. Cybersecurity - 2026-03-09
Cartesian Therapeutics, Inc. disclosed their cybersecurity strategy, risk management and governance process in an annual SEC Filing 10-K filing on 2026-03-09 07:05:18 EDT
Company Summary
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company developing autologous mRNA cell therapies (mRNA CAR-T) to treat autoimmune diseases, supported by a proprietary technology and in-house cGMP manufacturing platform (lead candidates include Descartes-08 and Descartes-15).
Filings
10-K filed on 2026-03-09
Cartesian Therapeutics, Inc. filed an SEC Filing 10-K filing on 2026-03-09 07:05:18 EDT.
Accession Number: 0001453687-26-000064
Item 1C. Cybersecurity
Item 1C - Cybersecurity
Item 1C. Cybersecurity
One of the key responsibilities of our Board of Directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our Board of Directors administers its cybersecurity risk oversight function directly and through the Audit Committee, which conducts regular risk assessments related to all matters affecting the enterprise, including cybersecurity, and receives periodic reports on the Company's cybersecurity risks and activities. Our Chief Financial Officer and our Senior Director, Head of IT are the Company employees responsible for developing and implementing a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. We partner with external cybersecurity vendors to enact a layered defense approach with controls deployed that seek to meet the requirements of the NIST Cybersecurity Framework.
Our Chief Financial Officer has served as a biotechnology executive for over 20 years, whose responsibilities have included direct oversight of his companies' cybersecurity risks. Our Senior Director, Head of IT has served as an Information Technology professional for over fifteen years and has held senior IT positions across several companies including a large pharmaceutical company.
We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. Our Senior Director, Head of IT oversees the cybersecurity program through risk management, employee security training, and oversight and escalation of threat monitoring and incident response. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. In the event of a major security incident, we have established an escalation path for stakeholder notification and remediation efforts, and major incidents are immediately escalated to the Head of IT, Chief Financial Officer, and Chief Operations Officer. In 2024, an external partner conducted a robust cybersecurity assessment to evaluate our risk profile. We are leveraging these insights to strengthen our key defenses and continuously mature our security posture. We have implemented processes when evaluating third-party service providers, for example by reviewing available audit reports including the System and Organization Controls (SOC 2) reports and requesting disclosure of any previous cybersecurity events. We also perform quality audits of our regulated vendors, which includes an assessment of the vendor's information technology system and associated controls.
Additionally, we conduct periodic risk assessments to identify and monitor against potential cybersecurity threats and incidents, as well as assess for any changes in our business practices that may affect our cybersecurity position. This risk oversight includes identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.
Following these risk assessments, we re-design, implement, and maintain reasonable safeguards to minimize identified risks and address any identified gaps in existing safeguards. Primary responsibility for assessing, monitoring and managing our cybersecurity program is delegated to our Senior Director, Head of IT, who reports on IT operations, risk mitigation and assessment efforts, and other general cybersecurity matters to our Chief Financial Officer, to manage the risk assessment and mitigation process.
As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards.
We continue to work with third-party cybersecurity vendors to assist us in best practices for implementing strengthened cybersecurity procedures . All Company employees and third-party vendors are instructed to promptly report any suspected breach of its security measures that may affect our Company to the Senior Director, Head of IT. Our Chief Financial Officer and Senior Director, Head of IT provide periodic briefings to the Audit Committee regarding our Company's cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third-parties, and related matters. The Audit Committee provides regular updates to the full Board of Directors on such reports.
We have not encountered cybersecurity challenges that have materially impaired our operations or financial standing. For additional information regarding risks from cybersecurity threats, please refer to Item 1A, "Risk Factors," in this Annual Report on Form 10-K.
Company
Profile
| Name | Cartesian Therapeutics, Inc. |
|---|---|
| CIK | 1453687 |
| SIC Description | |
| Industry | |
| Ticker | RNAC |
| Website | http://www.selectabio.com |
| Category | Non-accelerated Filer |
| Fiscal Year End | December 31 |